Tag Archives: Johnson & Johnson

← Older posts Newer posts →

IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

About six months after the FDA approved the first treatment for peanut allergy, a new biotech, IgGenix, has raised $10 million to discover antibodies that could address that and other common allergies. The six-person startup, which is based out of the Johnson & Johnson (NYSE: JNJ) JLABS incubator in South San Francisco, raised the Series […]

Posted in National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on IgGenix Grabs $10M to Advance Antibody Treatments for Allergies

Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More

EQRx launched in January during the JP Morgan Healthcare Conference with an audacious pledge to create 10 new drugs in as many years and then sell them at “dramatically” lower prices than existing medicines. But it offered few specifics about how it would achieve those goals. This week, drug licensing deals it made with two […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More

MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy

A gene therapy being jointly developed by MeiraGTx and Johnson & Johnson to treat an inherited disease of the retina that leads to blindness improved patients’ vision after six months, data that the companies say is enough to move the potentially long-lasting treatment into pivotal testing. The condition, called X-linked retinitis pigmentosa, is part of […]

Posted in Europe blog main, National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , | Comments Off on MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy

Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a […]

Posted in National blog main, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs

Targeted therapies for treating cancer are designed to attack one or more proteins known to be on the surface of cancerous cells—but they don’t discriminate when they come across healthy cells expressing those same proteins. Vor Biopharma, an oncology company launched by Boston biotech PureTech Health in 2016, has raised $110 million in private financing […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs

Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients

Fast enrollment of the right patient populations will be critical to quickly conducting Phase III trials of COVID-19 vaccines and this will likely mean taking concerted steps to reach out to populations that can be harder to recruit for clinical trials, drug industry leaders said on a recent New York Academy of Sciences webinar. Moderna […]

Posted in Boston blog main, Boston top stories, Europe blog main, National, National blog main, New York blog main, New York top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , | Comments Off on Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine

Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test. The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: MRNA) announced Thursday. Those patients will be randomly assigned to receive either […]

Posted in Boston, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , | Comments Off on Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine

AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal

In one of the largest oncology partnerships ever, AbbVie and Genmab are teaming up to accelerate development and commercialization of three of the Danish biotech’s investigational bispecific antibody drugs and potentially develop more. North Chicago, IL-based AbbVie (NYSE: ABBV) is spending $750 million up front to kick off the effort, which involves two clinical-stage drugs, […]

Posted in Europe blog main, Europe top stories, National, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal← Older posts Newer posts →